Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRM-CHOP for CD5-positive diffuse large B-cell lymphoma
ChiCTR2200067056Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IRM + CHOP in diffuse large B-cell lymphoma (DLBCL), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Objective response rate, Complete remission rate and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
IRM + CHOP
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2200067056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067056.